Latest & greatest articles for heparin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on heparin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on heparin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for heparin

102. Oral direct factor Xa inhibitors versus low-molecular-weight heparin to prevent venous thromboembolism in patients undergoing total hip or knee replacement: a systematic review and meta-analysis

Oral direct factor Xa inhibitors versus low-molecular-weight heparin to prevent venous thromboembolism in patients undergoing total hip or knee replacement: a systematic review and meta-analysis Oral direct factor Xa inhibitors versus low-molecular-weight heparin to prevent venous thromboembolism in patients undergoing total hip or knee replacement: a systematic review and meta-analysis Oral direct factor Xa inhibitors versus low-molecular-weight heparin to prevent venous thromboembolism (...) in patients undergoing total hip or knee replacement: a systematic review and meta-analysis Neumann I, Rada G, Claro JC, Carrasco-Labra A, Thorlund K, Akl EA, Bates SM, Guyatt GH CRD summary This review concluded that compared with low-molecular-weight heparin, low doses of oral factor Xa inhibitors achieved a small absolute reduction in symptomatic deep vein thrombosis without the increase in bleeding associated with high doses. Despite problems with missing data these conclusions appear likely

DARE.2012

103. Heparin-induced skin lesions.

Heparin-induced skin lesions. Heparins are widely used for prophylaxis and treatment of thromboembolic diseases. Besides bleeding complications, heparin-induced skin lesions are the most frequent unwanted adverse effects of subcutaneous heparin treatment. Evidence suggests that these lesions are more common than previously thought. Lesions are most frequently due to either allergic reactions or to possibly life-threatening heparin-induced thrombocytopenia. Early recognition and adequate (...) treatment are highly important, because although both complications initially show a similar clinical picture, their treatment should be fundamentally different. Furthermore, risk factors associated with the patient, drug, and treatment regimen have been identified. We review the clinical range of heparin-induced skin lesions, emphasise evidence and controversies in epidemiology, diagnosis, and differential diagnosis, and discuss the management of patients with these skin lesions. Copyright © 2012

Lancet2012

104. Low-molecular-weight heparin versus unfractionated heparin for prophylaxis of venous thromboembolism in medicine patients: a pharmacoeconomic analysis

Low-molecular-weight heparin versus unfractionated heparin for prophylaxis of venous thromboembolism in medicine patients: a pharmacoeconomic analysis Low-molecular-weight heparin versus unfractionated heparin for prophylaxis of venous thromboembolism in medicine patients: a pharmacoeconomic analysis Low-molecular-weight heparin versus unfractionated heparin for prophylaxis of venous thromboembolism in medicine patients: a pharmacoeconomic analysis Wilbur K, Lynd LD, Sadatsafavi M Record Status (...) This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study assessed the cost-effectiveness of low-dose unfractionated heparin versus low-molecular weight heparin (LMWH) for the prevention of venous thromboembolism, in patients hospitalised for non-surgical

NHS Economic Evaluation Database.2012

105. Early intravenous unfractionated heparin and mortality in septic shock

Early intravenous unfractionated heparin and mortality in septic shock PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

PedsCCM Evidence-Based Journal Club2012

106. Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of acute ST-segment elevation myocardial infarction

Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of acute ST-segment elevation myocardial infarction 22313548 2012 03 16 2012 05 22 2016 11 25 1468-201X 98 7 2012 Apr Heart (British Cardiac Society) Heart Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of acute ST-segment elevation myocardial infarction. 544-51 10.1136/heartjnl-2011-301323 To assess the cost-effectiveness of bivalirudin (...) versus heparin and glycoprotein IIb/IIIa inhibitor (H-GPI) in patients undergoing primary percutaneous coronary intervention (PPCI) for acute ST-segment elevation myocardial infarction (STEMI), from a UK health service perspective. Cost-utility analysis with life-long time horizon. Costs, quality-adjusted life-years (QALYs) and incremental cost-effectiveness. Event risks and medical resource use data derived from the HORIZONS-AMI trial were entered into a decision analytic model. Clinical events

EvidenceUpdates2012

107. Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: systematic review and meta-analysis

Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: systematic review and meta-analysis Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: systematic review and meta-analysis Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: systematic review and meta-analysis Silvain J, Beygui F, Barthelemy O, Pollack C, Cohen M, Zeymer U, Huber (...) K, Goldstein P, Cayla G, Collet JP, Vicaut E, Montalescot G CRD summary The review concluded that enoxaparin seemed to be superior to unfractionated heparin in reducing mortality and bleeding outcomes during percutaneous coronary intervention, particularly for primary intervention in patients with ST elevation myocardial infarction. The authors' conclusions appear reasonable and are likely to be reliable. Authors' objectives To determine the efficacy and safety of enoxaparin compared

DARE.2012

108. Cost-effectiveness of rivaroxaban versus heparins for prevention of venous thromboembolism after total hip or knee surgery in Sweden

Cost-effectiveness of rivaroxaban versus heparins for prevention of venous thromboembolism after total hip or knee surgery in Sweden Cost-effectiveness of rivaroxaban versus heparins for prevention of venous thromboembolism after total hip or knee surgery in Sweden Cost-effectiveness of rivaroxaban versus heparins for prevention of venous thromboembolism after total hip or knee surgery in Sweden Ryttberg L, Diamantopoulos A, Forster F, Lees M, Fraschke A, Bjorholt I Record Status (...) This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study assessed the cost-effectiveness of rivaroxaban versus two low-molecular-weight heparin (LMWH) treatments (enoxaparin and dalteparin) for the prevention of venous thromboembolism, after total hip or knee

NHS Economic Evaluation Database.2012

109. A randomized trial comparing gentamicin/citrate and heparin locks for central venous catheters in maintenance hemodialysis patients

A randomized trial comparing gentamicin/citrate and heparin locks for central venous catheters in maintenance hemodialysis patients 22088576 2011 12 19 2012 02 13 2013 11 21 1523-6838 59 1 2012 Jan American journal of kidney diseases : the official journal of the National Kidney Foundation Am. J. Kidney Dis. A randomized trial comparing gentamicin/citrate and heparin locks for central venous catheters in maintenance hemodialysis patients. 102-7 10.1053/j.ajkd.2011.08.031 Central venous (...) patients who were using a tunneled cuffed CVC for vascular access. The treatment group received an antibiotic lock containing gentamicin 320 μg/mL in 4% sodium citrate, whereas the control group received the standard catheter lock containing heparin 1,000 U/mL. Both groups received triple-antibiotic ointment on the catheter exit site during dressing changes at each dialysis treatment. Catheter-related bloodstream infection and catheter clotting. Catheter-related bloodstream infection was defined

EvidenceUpdates2012

110. A multicenter, randomized trial comparing heparin/warfarin and acetylsalicylic acid as primary thromboprophylaxis for 2 years after the Fontan procedure in children

A multicenter, randomized trial comparing heparin/warfarin and acetylsalicylic acid as primary thromboprophylaxis for 2 years after the Fontan procedure in children PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

PedsCCM Evidence-Based Journal Club2012

111. [Heparin-bonded vascular prostheses for the treatment of peripheral artery disease]

[Heparin-bonded vascular prostheses for the treatment of peripheral artery disease] Prótesis vasculares recubiertas con heparina para el tratamiento de la enfermedad arterial periférica [Heparin-bonded vascular prostheses for the treatment of peripheral artery disease] Prótesis vasculares recubiertas con heparina para el tratamiento de la enfermedad arterial periférica [Heparin-bonded vascular prostheses for the treatment of peripheral artery disease] Pichon Riviere A, Augustovski F, Garcia (...) . [Heparin-bonded vascular prostheses for the treatment of peripheral artery disease] Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS). Informe de Respuesta Rápida N°252. 2012 Authors' objectives To assess the evidence available on the safety, efficacy and other aspects related to coverage polices of the use of heparin-bonding vascular prosthesis for the treatment of peripheral artery occlusion. Authors' conclusions Short and long-term primary and secondary permeability rates

Health Technology Assessment (HTA) Database.2012

112. Prophylaxis for thromboembolic disease with low molecular weight heparins in adult patients in home care

Prophylaxis for thromboembolic disease with low molecular weight heparins in adult patients in home care Profilaxis de enfermedad tromboembólica con heparinas de bajo peso molecular en pacientes adultos en internación domiciliaria [Prophylaxis for thromboembolic disease with low molecular weight heparins in adult patients in home care] Profilaxis de enfermedad tromboembólica con heparinas de bajo peso molecular en pacientes adultos en internación domiciliaria [Prophylaxis for thromboembolic (...) disease with low molecular weight heparins in adult patients in home care] Pichon Riviere A, Augustovski F, Garcia Marti S, Glujovsky D, Alcaraz A, Lopez A, Bardach A, Ciapponi A, Urtasun M Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Pichon Riviere A, Augustovski F, Garcia Marti S, Glujovsky D, Alcaraz A, Lopez A, Bardach A, Ciapponi

Health Technology Assessment (HTA) Database.2012

113. Randomised controlled trial: Flushing of intravenous locks in neonates: no evidence that heparin improves patency compared with saline

Randomised controlled trial: Flushing of intravenous locks in neonates: no evidence that heparin improves patency compared with saline Flushing of intravenous locks in neonates: no evidence that heparin improves patency compared with saline | Evidence-Based Nursing This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in via your Society Log in using your username and password For personal accounts OR managers of institutional accounts Username (...) * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in via your Society Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Flushing of intravenous locks in neonates: no evidence that heparin improves patency compared with saline Article Text Child health Randomised controlled trial Flushing of intravenous locks in neonates: no evidence

Evidence-Based Nursing (Requires free registration)2012

114. Meta-analysis of safety and efficacy of uninterrupted warfarin compared to heparin-based bridging therapy during implantation of cardiac rhythm devices

Meta-analysis of safety and efficacy of uninterrupted warfarin compared to heparin-based bridging therapy during implantation of cardiac rhythm devices Meta-analysis of safety and efficacy of uninterrupted warfarin compared to heparin-based bridging therapy during implantation of cardiac rhythm devices Meta-analysis of safety and efficacy of uninterrupted warfarin compared to heparin-based bridging therapy during implantation of cardiac rhythm devices Ghanbari H, Saint Phard W, Al-Ameri H (...) . Authors' objectives To assess the efficacy and safety of perioperative heparin-based bridging therapy versus uninterrupted warfarin therapy in patients undergoing pacemaker or implantable cardioverter-defibrillator implantation. Searching MEDLINE (1950 to 2012), EMBASE (1988 to 2012), Cochrane Central Register of Controlled Trials (CENTRAL) (fourth quarter 2011) were searched for studies published in English. Search terms were reported. Reports presented at scientific meetings and relevant conference

DARE.2012

115. Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of acute ST-segment elevation myocardial infarction

Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of acute ST-segment elevation myocardial infarction Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of acute ST-segment elevation myocardial infarction Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of acute ST-segment elevation myocardial infarction Schwenkglenks M, Toward TJ, Plent (...) -segment elevation myocardial infarction. The authors' concluded that bivalirudin was a cost-effective alternative to heparin plus a glycoprotein IIb/IIIa inhibitor. UK clinical practice appeared to be slightly different to that used in the trial that supplied the data, but the results were robust and the authors' conclusions are appropriate. Type of economic evaluation Cost-utility analysis Study objective The objective was to assess the cost-effectiveness of bivalirudin, for patients receiving

NHS Economic Evaluation Database.2012

116. A diagnosis of heparin-induced thrombocytopenia with combined clinical and laboratory methods in cardiothoracic surgical intensive care unit patients

A diagnosis of heparin-induced thrombocytopenia with combined clinical and laboratory methods in cardiothoracic surgical intensive care unit patients 21788317 2011 09 28 2012 07 16 2015 11 19 1526-7598 113 4 2011 Oct Anesthesia and analgesia Anesth. Analg. A diagnosis of heparin-induced thrombocytopenia with combined clinical and laboratory methods in cardiothoracic surgical intensive care unit patients. 697-702 10.1213/ANE.0b013e3182297031 Diagnosing postoperative heparin-induced (...) thrombocytopenia (HIT) in cardiothoracic surgical patients is complicated because of the profound thrombocytopenia that occurs with cardiopulmonary bypass (CPB). CPB predisposes patients to develop a frequent incidence of antibodies directed against platelet factor 4 (PF4)/heparin complexes and HIT. The sensitivity of readily available antibody immunoassays is high, but specificity is quite low. The use of both a clinical probability score and rapid laboratory immunoassay has been shown to increase specificity

EvidenceUpdates2012

117. Diagnosis and management of Heparin induced thrombocytopenia: second edition

Diagnosis and management of Heparin induced thrombocytopenia: second edition Guidelines on the diagnosis and management of heparin-induced thrombocytopenia: second edition - Watson - 2012 - British Journal of Haematology - Wiley Online Library By continuing to browse this site you agree to us using cookies as described in Navigate this article Previous article in issue: Molecular mechanisms of pathology and treatment in Diamond Blackfan Anaemia Next article in issue: Guidelines on the diagnosis (...) heparin should have a baseline platelet count (2C). Post-operative patients including obstetric cases receiving unfractionated heparin (UFH) should have platelet count monitoring performed every 2–3 d from days 4 to 14 or until heparin is stopped (2C). Post-cardiopulmonary bypass patients receiving low molecular weight heparin (LMWH) should have platelet count monitoring performed every 2–3 d from days 4 to 14 or until heparin is stopped (2C). Post-operative patients (other than cardiopulmonary bypass

British Committee for Standards in Haematology2012

118. Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of non-ST-segment elevation acute coronary syndromes

Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of non-ST-segment elevation acute coronary syndromes Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of non-ST-segment elevation acute coronary syndromes Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of non-ST-segment elevation acute coronary syndromes Schwenkglenks M, Brazier JE (...) , Szucs TD, Fox KA Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the cost-effectiveness of bivalirudin compared with heparin plus glycoprotein IIb/IIIa inhibitor in thienopyridine-treated patients with non-ST-segment

NHS Economic Evaluation Database.2011

119. Heparin-binding protein: A diagnostic marker of acute bacterial meningitis

Heparin-binding protein: A diagnostic marker of acute bacterial meningitis 21200320 2011 05 25 2011 07 29 2015 11 19 1530-0293 39 4 2011 Apr Critical care medicine Crit. Care Med. Heparin-binding protein: a diagnostic marker of acute bacterial meningitis. 812-7 10.1097/CCM.0b013e318206c396 The early detection of bacterial meningitis is crucial for successful outcome. Heparin-binding protein, a potent inducer of increased vascular permeability, is released from activated neutrophils in severe (...) sepsis. In this study we investigated whether heparin-binding protein levels in cerebrospinal fluid could be used as a diagnostic marker for acute bacterial meningitis. One prospective and one retrospective patient cohort from two university hospitals in Sweden were analyzed. Cerebrospinal fluid samples were collected from 174 patients with suspected central nervous system infection. Thirty-seven patients with acute community-acquired bacterial meningitis, four patients with neurosurgical bacterial

EvidenceUpdates2011